MDT Medtronic
Steady medtech compounder; new growth drivers support a value near fair, not a bargain.
The story
Medtronic is the largest diversified medtech company, spanning cardiac rhythm, structural heart, surgical, neuromodulation and diabetes. Its moat comes from hospital relationships, regulatory barriers and installed bases. It is a mature franchise in a mid-cycle reacceleration, driven by pulsed-field ablation, renal denervation and the Hugo surgical robot. The MiniMed diabetes separation simplifies the portfolio but takes away some growth.
The reported 0.49 sales-to-capital is inflated by goodwill from the Covidien deal, which is sunk capital. Organic, tuck-in growth needs far less capital, so I use 1.6 at the margin. That accounts for most of the gap between the baseline 20.66 and the 104.84 price. The 23% target margin sits between GAAP (about 19.5%, which includes acquisition amortization) and the adjusted figure (about 26%), reflecting mix shift toward higher-margin products and cost programs. Growth starts at 5%, in line with the 5-year CAGR, and fades to 3% because the business is mature but tied to demographic demand.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 23.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 0.85 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.2% |
| Terminal WACC | 8.8% |
Valuation bridge
| PV of explicit FCFF | 38.26B |
| PV of terminal value | 58.33B |
| Equity value | 68.62B |
| ÷ shares → per share | $53.65 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 39.42B | 5.0% | 20.2% | 6.28B | 1.17B | 5.11B | 4.72B |
| 2 | 41.28B | 4.7% | 20.9% | 6.80B | 1.16B | 5.64B | 4.82B |
| 3 | 43.10B | 4.4% | 21.6% | 7.34B | 1.14B | 6.20B | 4.89B |
| 4 | 44.89B | 4.1% | 22.3% | 7.89B | 1.12B | 6.78B | 4.94B |
| 5 | 46.62B | 3.9% | 23.0% | 8.45B | 1.08B | 7.37B | 4.97B |
| 6 | 48.29B | 3.6% | 23.0% | 8.75B | 1.04B | 7.71B | 4.81B |
| 7 | 49.87B | 3.3% | 23.0% | 9.04B | 991.60M | 8.05B | 4.64B |
| 8 | 51.37B | 3.0% | 23.0% | 9.31B | 935.12M | 8.38B | 4.46B |
Key risks
- The pulsed-field ablation share gain stalls against Boston Scientific and J&J, or Hugo adoption lags Intuitive
- Hospital pricing pressure, tariffs and policy changes in China and the US squeeze margins
- Product recalls or quality and FDA warning-letter issues, plus dis-synergies from the diabetes separation
Catalysts
- Ramp in PFA and renal denervation reimbursement (CMS coverage) lifting growth to the high single digits
- Completion of the MiniMed separation and capital returns from deleveraging